MD Anderson Cancer Center
Iressa As Effective As Chemotherapy for Lung Cancer Treatment – CNL
Groundbreaking study results suggest the drug Iressa has been proven to be just as effective as chemotherapy for treating lung cancer. The Iressa in Non-small cell lung cancer Trial Evaluating REsponse and Survival versus Taxotere (INTERST) study was a randomized phase III clinical trial evaluating the survival rate between IRESSA and docetaxel chemotherapy. These findings represent the first time an oral therapy has been tested head-to-head against standard therapy and surprising biomarker results. Edward Kim, M.D., a lead researcher in the INTERST Study, discusses the international Phase III clinical trial.

Transcript Transcript     Accessibility shortcut keys (H) Shortcuts
Loading the Audio Player...

Title: Iressa As Effective As Chemotherapy for Lung Cancer Treatment – CNL
Summary: Groundbreaking study results suggest the drug Iressa has been proven to be just as effective as chemotherapy for treating lung cancer. The Iressa in Non-small cell lung cancer Trial Evaluating REsponse and Survival versus Taxotere (INTERST) study was a randomized phase III clinical trial evaluating the survival rate between IRESSA and docetaxel chemotherapy. These findings represent the first time an oral therapy has been tested head-to-head against standard therapy and surprising biomarker results. Edward Kim, M.D., a lead researcher in the INTERST Study, discusses the international Phase III clinical trial.
Keywords:
Transcript: http://www.mdanderson.org/transcripts/CNL_Iressa_Treatment__Lung_Cancer_Transcript.html